Loading...
Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
70% to 90% • 25%
More than 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
More than 300,000 • 25%
200,000-300,000 • 25%
100,000-200,000 • 25%
Less than 100,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
Less than 1 million • 25%
1-2 million • 25%
2-3 million • 25%
More than 3 million • 25%
Less than 25% • 25%
25% to 50% • 25%
More than 75% • 25%
50% to 75% • 25%
Children • 25%
Elderly • 25%
Immunocompromised • 25%
General population • 25%
Ages 19-64 • 25%
Ages 5-18 • 25%
Elderly over 65 • 25%
Children under 5 • 25%
10 million to 15 million • 25%
5 million to 10 million • 25%
More than 15 million • 25%
Less than 5 million • 25%
Less than 50% • 25%
More than 90% • 25%
70% to 90% • 25%
50% to 70% • 25%